Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription factor E2F4 (E2F4) is a member of the E2F family of transcription factors, which are critical regulators of cell cycle progression, DNA repair, apoptosis, and differentiation. E2F4 primarily acts as a transcriptional repressor via interactions with the pocket proteins p130 (RBL2) and p107 (RBL1), forming complexes that inhibit expression of proliferation-associated genes, but can also function as an activator in certain contexts[1][2][4]. It plays a role in enforcing cell cycle arrest, particularly in quiescent cells, and can bind to both promoters and distal genomic regions, influencing expression of protein-coding genes and non-coding RNAs; aberrant expression or mutation of E2F4 has been linked to oncogenic processes and human cancers[1][3][2][4].
Transcriptional repression via recruitment of pocket proteins (p130, p107, pRB); Formation of repressor complexes; Modulation of cell cycle and cell fate genes; Regulation of enhancer elements at distal genomic sites
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription factor E2F4 (E2F4).